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Summary
Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in 
patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs 
would improve efficacy compared with previously published data on either regimen alone.
Methods In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with 
relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing 
regimen, an Eastern Cooperative Oncology Group performance status score of 0–3, and at least one site of measurable 
disease, and who met criteria for several laboratory-assessed parameters. Treatment was divided into an induction 
phase of 12 cycles of 28 days with all three drugs and a maintenance phase with ibrutinib and rituximab only (cycle 
duration 56 days), given until disease progression or unacceptable toxicity. In the induction phase, patients received 
intravenous (375 mg/m²) or subcutaneous (1400 mg) rituximab once a week during cycle 1 and then once every 
8 weeks. Oral ibrutinib (560 mg once a day) was given to patients every day in the cycle, whereas oral lenalidomide 
(15 mg once a day) was given on days 1–21. The primary endpoint was overall response assessed in the intention-to-
treat population according to Lugano criteria. Safety analysis included all patients who received the treatment, 
irrespective of eligibility or duration of treatment. The trial is ongoing, but is no longer accruing patients, and is 
registered with ClinicalTrials.gov, number NCT02460276.
Findings Between April 30, 2015, and June 1, 2016, we enrolled 50 patients with relapsed or refractory mantle cell 
lymphoma at ten centres in Sweden, Finland, Norway, and Denmark. At a median follow-up of 17·8 months 
(IQR 14·7–20·9), 38 (76%, 95% CI 63–86) patients had an overall response, including 28 (56%, 42–69) patients who 
had a complete response and ten (20%, 11–33) who had a partial response. The most common grade 3–4 adverse 
events were neutropenia (in 19 [38%] of 50 patients), infections (in 11 [22%] patients), and cutaneous toxicity 
(in seven [14%] patients). There were three treatment-related deaths during the study, two due to sepsis and one due 
to embolic stroke.
Interpretation Our results provide preliminary evidence that the triplet combination of ibrutinib, lenalidomide, and 
rituximab is an active regimen in patients with relapsed or refractory mantle cell lymphoma, and should be evaluated 
in a prospective randomised controlled trial.
Funding Janssen and Celgene.
Introduction
Relapsed or refractory mantle cell lymphoma is 
associated with poor outcomes. The choice of therapy 
depends on the efficacy of previous lines of treatment.1 
In many cases of disease progression, a non-cross-resistant 
chemotherapy regimen is the next choice, usually in 
combination with the anti-CD20 antibody rituximab. 
In patients with chemorefractory disease or early relapse, 
non-chemotherapeutic alternatives might be considered. 
Among such drugs active in relapsed or refractory mantle 
cell lymphoma are bortezomib, temsirolimus, lenali-
domide, ibrutinib, and venetoclax.2–6 Lenalidomide is an 
immunomodulatory drug with antiangiogenic and 
antineoplastic properties. In B-cell malignancies, lenali-
domide interacts with the ubiquitin E3 ligase cereblon 
and enhances its enzymatic activity to degrade the 
transcription factors IKZF1 (DNA-binding protein 
Ikaros) and IKZF3 (zinc finger protein Aiolos), leading to 
reduced activity of IRF4 (interferon regulatory factor 4), 
a downstream target of cereblon. This downregulation of 
IRF4 leads to proliferation and activation of natural killer 
cells, thereby enhancing natural killer cell-mediated 
cytotoxicity and antibody-dependent cellular cytotoxicity.7 
In this respect, lenalidomide acts as an immunosensitiser, 
enhancing the activity of rituximab. The combination of 
rituximab and lenalidomide has been shown to be very 
active in mantle cell lymphoma, in both relapsed and 
front-line settings.8,9
The introduction of ibrutinib, an inhibitor of Bruton’s 
tyrosine kinase, was considered a major step forward in 
the treatment of mantle cell lymphoma. Its activity is 
substantially higher than other single drugs used in the 
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treatment of this cancer, with 65–70% of patients having 
a confirmed response in both phase 2 and phase 3 trials.5,10 
Because ibrutinib also modulates the microenvironment 
in vivo, synergy with the immunosensitising effects of 
lenalidomide could be expected.11 Ibrutinib in com-
bination with lenalidomide might also counteract 
possible antagonism between ibrutinib and rituximab.12,13
Based on the high activity and good tolerability of both 
ibrutinib alone and rituximab and lenalidomide in 
combination, we aimed to assess the efficacy and safety 
of the triplet combination in patients with relapsed or 
refractory mantle cell lymphoma. Moreover, we aimed to 
investigate the proportion of patients who achieved 
molecular remission with this regimen and its activity 
with regard to specific mutations commonly present in 
mantle cell lymphoma, such as TP53 mutations, which 
are associated with poor outcomes in the front-line 
setting.14
Methods
Study design and participants
We did an open-label, single-arm, multicentre, 
phase 2 trial at ten centres in Sweden, Finland, Norway, 
and Denmark (appendix p 8). Eligible patients were older 
than 18 years; had previously been treated with at least 
one rituximab-containing regimen, with no upper limit 
on the number of previous treatments received; and had 
histologically confirmed mantle cell lymphoma, an 
Eastern Cooperative Oncology Group performance status 
score of 0–3, at least one site of measurable disease 
(>1·5 cm long axis), an absolute neutrophil count of 
1000 cells per μL or higher, a platelet count of 
100 000 per μL or higher (or ≥50 000 per μL in cases of 
bone marrow involvement), alanine aminotransferase 
and aspartate aminotransferase levels three times lower 
than the upper limit of normal, and serum creatinine 
concentrations no greater than two times the upper limit 
of normal. A washout period of 3 weeks since previous 
therapy was required. Key exclusion criteria included 
known CNS involvement, HIV infection, active hepatitis 
B or C virus infection, stroke or intracranial haemorrhage 
(within 6 months before enrolment), need for 
anticoagulation with warfarin (or equivalent vitamin K 
antagonist), or treatment with strong or moderate CYP3A 
(cytochrome P450 3A4) inhibitors. Previous treatment 
with ibrutinib or lenalidomide was allowed.
The study was approved by the national ethics 
committee in each country and done according to the 
Declaration of Helsinki and International Conference on 
Harmonisation guidelines for Good Clinical Practice. 
All patients provided written informed consent.
Procedures
At the time of initiation of this study, a phase 1 trial15 
of the combination of ibrutinib, rituximab, and 
lenalidomide in patients with follicular lymphoma was 
ongoing. We selected doses of lenalidomide and ibrutinib 
on the basis of this previous trial.15 Treatment was divided 
into an induction phase of 12 cycles of 28 days with all 
three drugs and a maintenance phase with ibrutinib and 
rituximab only (cycle duration 56 days), given until 
disease progression or unacceptable toxicity. Patients 
received rituximab once a week for 4 weeks during 
cycle 1, then every 8 weeks. The initial dose of rituximab 
See Online for appendix
Research in context
Evidence before this study
We searched PubMed without language restrictions for clinical 
trials published up to Dec 5, 2013, using the search term 
“ibrutinib, rituximab, and lenalidomide”. We also searched the 
EU Clinical Trials Register and ClinicalTrials.gov using the same 
search term. We found no trials examining the combination of 
these drugs in the treatment of mantle cell lymphoma. At the 
annual meeting of the American Society of Hematology in 
December, 2015, Ujjani and colleagues presented the results of 
a phase 1 trial of lenalidomide, rituximab, and ibrutinib in 
previously untreated patients with follicular lymphoma. They 
found no clear benefit for the triplet regimen over the 
combination of rituximab and lenalidomide in terms of efficacy, 
but a high incidence of grade 3 cutaneous toxicity (36%).
Added value of this study
To the best of our knowledge, this study is the first to assess the 
non-chemotherapeutic combination of lenalidomide, rituximab, 
and ibrutinib in patients with relapsed or refractory mantle cell 
lymphoma. Compared with previous studies of ibrutinib alone or 
in combination with rituximab, the triplet regimen was 
associated with increased haematological toxicity and infections, 
but also appeared to be more active in terms of complete 
responses. The effect of specific mutations and copy-number 
alterations has not previously been investigated in a prospective 
clinical trial of a non-chemotherapy regimen for mantle cell 
lymphoma. We showed that the combination of lenalidomide, 
rituximab, and ibrutinib might overcome the adverse prognostic 
effects of TP53 mutations and CDKN2A-TP53 deletions. 
Additionally, evaluation of minimal residual disease in bone 
marrow and peripheral blood with real-time PCR has not 
previously been reported in a trial of a non-chemotherapeutic 
regimen for mantle cell lymphoma. We found that a molecular 
remission could be obtained in a high proportion of patients, 
including in those with TP53 mutation.
Implications of all the available evidence
Our findings indicate that the combination of lenalidomide, 
rituximab, and ibrutinib might be an active regimen in patients 
with relapsed or refractory mantle cell lymphoma, particularly 
in the subset of patients with high-risk genetic features, such as 
TP53 mutations or combined deletions of TP53 and CDKN2A. 
For this subset of patients, the triplet regimen might be used as 
a bridge to allogeneic stem-cell transplantation.
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was given intravenously at 375 mg/m²; subsequent doses 
could then either be given intravenously at the same dose 
or as a subcutaneous injection of 1400 mg to remove the 
need for intravenous access. No dose reductions were 
permitted for rituximab. Ibrutinib was given orally 
(560 mg once a day) on days 1–28, and lenalidomide was 
given orally (15 mg once a day) on days 1–21. Doses of 
lenalidomide and ibrutinib were reduced in cases of 
grade 3 or 4 neutropenia and thrombocytopenia. In such 
cases, ibrutinib was reduced from 560 mg per day to 
420 mg per day and then to 280 mg per day; lenalidomide 
was reduced from 15 mg per day to 10 mg per day and 
then to 5 mg per day.
Study treatment was terminated in cases of progressive 
disease or grade 4 non-haematological toxicity, if requested 
by a patient, or if the treating physician thought a change 
of therapy would be in the best interest of the patient.
To assess minimal residual disease at baseline, DNA 
was extracted from lymphoma cells in bone marrow with 
the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, 
Germany) and used for design of primers for PCR 
amplification of patient-specific clonally rearranged 
immunoglobulin heavy chain genes (IGH) and detection 
of the CCND1-IGH translocation t(11;14). PCR was done 
with the TaqMan Gene Expression Master Mix (Thermo 
Fisher Scientific, Waltham, MA, USA). The sensitivity of 
the assay for minimal residual disease was one in 
10⁵ cells, except for four patients in whom the sensitivity 
of the assay was one in 10⁴ cells. For patients with less 
than 1% tumour cells in bone marrow at baseline, a 
quantitative assay for minimal residual disease was not 
feasible and, instead, a qualitative nested PCR assay was 
done, as previously described.16
For genetic analyses, we did next-generation sequen cing 
using Ion Torrent technology (ThermoFisher Scientific, 
Waltham, MA, USA) to analyse DNA from bone marrow 
specimens taken at baseline for mutations in selected 
coding regions, splice sites, and untranslated regions 
of ATM, KMT2D, CCND1, TP53, WHSC1, BIRC3, 
NOTCH1, and NOTCH2, as described previously.14 The 
cutoff for calling a variant was 5% in general and 3% for 
TP53 mutations. Median coverage for all runs was 2575 ×, 
and the limit for calling a variant was 400 ×. Chromosome 
17p13 (TP53) and chromosome 9p21 (CDKN2A) deletions 
were identified by droplet digital PCR with the QX200 
system (Bio-Rad Laboratories, Hercules, CA, USA), as 
described previously.14 Copy number loss was defined as 
copy number less than 1·95. Each sample was analysed at 
least twice and deletions were called with QuantaSoft 
software version 1.7 (Bio-Rad Laboratories, Hercules, CA, 
USA). The people who did the genetic analyses were 
masked to patient characteristics and outcomes.
Outcomes
The primary endpoint was overall response assessed 
according to Lugano criteria,17 with restaging every 
12 weeks during the induction phase according to results 
of CT and bone marrow examination. PET scans were 
done to confirm complete responses or at the time of 
maximal tumour regression. During the maintenance 
phase, CT and bone marrow examination were done 
every 6 months. Evaluation of CT and PET scans was 
done at the individual study centres.
Secondary endpoints included proportion of patients 
who achieved a complete response (assessed with and 
without PET), response duration (time from date of 
response to date of disease progression or death), 
proportion of patients who achieved molecular remission, 
molecular remission duration (time from date of 
molecular remission to date of molecular relapse or 
death), progression-free survival (time from enrolment 
to date of disease progression, death from any cause, or 
last available follow-up), and overall survival (time from 
enrolment to date of death or last available follow-up). 
In a post-hoc analysis, factors predictive of progression-
free and overall survival were evaluated. Safety was also a 
secondary endpoint, assessed with adverse event 
monitoring and laboratory analyses. Adverse events were 
assessed according to the Common Toxicity Criteria for 
Adverse Events, version 4.03. We also investigated the 
presence of biomarkers, including specific mutations 
and chromosomal deletions. Health-related quality of life 
was assessed with the European Organisation for 
Research and Treatment of Cancer QLQ-C30 question-
naire, although the results of this analysis will be reported 
elsewhere. Minimal residual disease in blood and bone 
marrow specimens after cycles 6, 12, 18, and 24 using 
real-time PCR, according to EuroMRD criteria, was also 
assessed as a secondary endpoint.18 Genetic analyses 
were exploratory. 
Statistical analysis
According to Fleming’s single-stage procedure (type I error 
α of 0·05 and power of 0·8), to achieve an overall 
response in more than 85% of patients (chosen to be 
superior to the 75 [68%] of 111 patients who had an overall 
response in a previous phase 2 trial5 of ibrutinib alone; 
p<0·05), 40 patients would need to be recruited. If 34 or 
more patients had a response, the null hypothesis could 
be rejected. The primary analysis was done by intention 
to treat. The safety analysis included all patients who 
received the treatment, irrespective of eligibility or 
duration of treatment. To account for loss of 20% of 
patients because of ineligibility and early progression, a 
total sample size of 50 patients was required.
Descriptive statistics were used to summarise patient 
demographics and baseline characteristics. We used the 
Kaplan-Meier method to estimate progression-free 
survival and overall survival. Univariate and multivariate 
analyses were done with the Cox proportional-hazards 
regression model. All statistical analyses were done with 
IBM SPSS version 22.0.
This trial is registered with ClinicalTrials.gov, number 
NCT02460276.
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Role of the funding source
The funders were not involved in the protocol writing, data 
collection, data analysis, data interpretation, or writing of 
the report, but did review the manuscript before 
submission. All authors had full access to the raw data and 
approved the final submitted version. The corresponding 
author had the final decision to submit for publication.
Results
Between April 30, 2015, and June 1, 2016, we enrolled 
50 patients with relapsed or refractory mantle cell 
lymphoma from ten centres in Sweden, Finland, Norway, 
and Denmark (figure 1). Table 1 shows the patients’ 
characteristics at baseline. 44 (88%) of 50 patients were 
evaluable for response with Lugano criteria. Six patients 
were not evaluable because of withdrawn consent (n=3) 
or discontinuation of treatment because of treatment-
related toxic effects, including sepsis (n=2) and fatigue 
(n=1), before response evaluation.
At a median follow-up of 17·8 months 
(IQR 14·7–20·9), 38 (76%, 95% CI 63–86) of 50 patients 
had an overall response (table 2). 28 (56%, 42–69) patients 
had a complete response and ten (20%, 11–33) had a 
partial response (table 2). Of the 27 patients in whom 
PET was done for response evaluation, 21 (78%) had a 
complete response, five (19%) had a partial response, and 
one (4%) had stable disease.
Median progression-free survival was 16·0 months 
(95% CI 13·7–20·5) and median overall survival 
was 22·0 months (19·5–23·8; figure 2); 12-month 
progression-free survival was 56·9% (95% CI 42·7–71·1) 
and 12-month overall survival was 77·6% (65·6–89·6). 
Overall median duration of response was not reached 
(95% CI not calculable). The 28 patients who achieved a 
complete response had a longer median duration of 
response (not reached [95% CI not calculable]) than the 
ten patients who achieved a partial response (8·9 months 
[95% CI 6·3–13·8]). Four patients who had disease 
progression on ibrutinib were included, of whom one 
achieved a partial response (which is still ongoing after 
13 months), one had stable disease, and two progressed 
early on study treatment. None of the eight patients with 
a low-risk score in the Mantle Cell Lymphoma 
International Prognostic Index (MIPI) progressed during 
the study. In an exploratory post-hoc analysis, MIPI score 
was the only factor predictive of outcome, in terms of 
progression-free survival (appendix p 9).
49 (98%) of 50 patients were evaluable for 
genetic aberrations associated with mantle cell 
lymphoma. We found no difference in overall response 
between patients with and without TP53 mutations 
(eight [73%, 95% CI 39–94] of 11 patients with mutations, 
including seven [64%, 31–89] with a complete response, 
vs 30 [79%, 63–90] of 38 patients without mutations, 
including 21 [55%, 38–71] with a complete response; 
table 2). Although patients with TP53 mutations appear 
to have longer progression-free survival, there was no 
difference in progression-free survival according to the 
univariate analysis (hazard ratio [HR] 2·0, 95% CI 
0·85–4·8, p=0∙11; appendix pp 1, 9), even after adjusting 
for MIPI score, sex, and deletion of CDKN2A and TP53 
in the multivariate analysis (2·6, 0·57–11·0, p=0∙22; 
appendix p 9). 14 patients presented with deletion of both 
CDKN2A and TP53, 12 (86%) of whom responded to 
treatment. The presence of a deletion in both CDKN2A 
and TP53 had no effect on progression-free or overall 
survival (appendix pp 2, 9). Similarly, we found no 
association between any other specific genetic abnor-
mality and outcome (data not shown).
Figure 1: Patient flow diagram
50 patients eligible for enrolment 
28 evaluable for molecular 
response at 6 months 
22 not evaluable for 
molecular response
11 follow-up samples 
not available
7 no lymphoma cells 
detected in bone 
marrow
4 no clonal marker 
identified 
1 not evaluable for 
genetic aberrations
(DNA not available)
6 not evaluable for 
response





44 evaluable for response 
with Lugano criteria
49 evaluable for genetic 
aberrations associated 
with mantle cell 
lymphoma
All patients (n=50)




ECOG performance status score 0–1 45 (90%)
MIPI score
Low risk (<5·7) 8 (16%)
Intermediate risk (5·7–6·1) 15 (30%)
High risk (>6·2) 23 (46%)
Missing 4 (8%)
Ann Arbor stage IV disease 42 (84%)
Bone marrow involvement 34 (68%)
Refractory disease 8 (16%)
Number of previous therapies 2 (1–7)
Previous therapy
Autologous stem-cell transplantation 21 (42%)
Allogeneic stem-cell transplantation 3 (6%)
Ibrutinib 4 (8%)
Lenalidomide 1 (2%)
Data are n (%) or median (range). ECOG=Eastern Cooperative Oncology Group. 
MIPI=Mantle Cell Lymphoma International Prognostic Index. 
Table 1: Patient and disease characteristics
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Of 49 patients with available DNA, 22 (45%) harboured 
at least one mutation in genes commonly mutated 
in mantle cell lymphoma (figure 3). The most common 
mutations were found in TP53 (in 11 [22%] patients), 
ATM (in eight [16%] patients), and KMT2D 
(in seven [14%] patients). Detailed information about the 
detected mutations can be found in the appendix (pp 6,7).
CDKN2A deletions were detected in 28 (58%) of 
48 evaluable patients and TP53 deletions in 17 (35%) of 
49 evaluable patients (figure 3). 14 (29%) of 48 patients 
presented with both deletions.
After 6 months, 28 (56%) of 50 patients were evaluable 
for minimal residual disease. 22 patients were not 
evaluable because follow-up samples were not available 
because of early progression or withdrawal (n=11), no 
lymphoma cells were detectable in bone marrow (n=7), 
or no clonal marker could be identified (n=4; figure 1). 
Primers for IGH rearrangements were used in all cases, 
and in seven patients with the t(11;14) translocation, 
primers to the CCND1-IGH rearrangement were used. 
Eight patients with less than 1% tumour cells in bone 
marrow at baseline were assessed for molecular 
remission with qualitative nested PCR. At 6 months, 
15 (56%) of 27 patients had molecular remission in 
peripheral blood and 12 (43%) had molecular remission 
in bone marrow. 13 (68%) of 19 patients had molecular 
remission in bone marrow at 12 months (table 3). The 
median duration of molecular remission was 3 months 
(IQR 3–9).
Patients who were negative for minimal residual 
disease in peripheral blood at 6 months had longer 
progression-free survival (median not reached [95% CI 
not calculable]) than patients who were positive for 
minimal residual disease in peripheral blood at 6 months 
(10·3 months [95% CI 5·6–15·0]; HR 0·14, 95% CI 
0·03–0·71; p=0·017; appendix p 3). The estimated 
24-month progression-free survival for patients with 
molecular remission at 6 months was 82% (95% CI 
69–96) compared with 42% (13–70) for patients not 
achieving molecular remission at 6 months. Furthermore, 
molecular remission in peripheral blood at 6 months was 
associated with longer overall survival (median not 
reached [95% CI not calculable] vs 20·0 months 
[9·8–31·0] for people who had not achieved molecular 
remission in peripheral blood at 6 months; 
HR 0·17, 95% CI 0·03–0·95; p=0·043); the estimated 
24-month overall survival for these patients was 
67% (95% CI 36–97), compared with 44% (16–72) for 
patients positive for minimal residual disease at 6 months 
(appendix p 4). Among four patients with TP53 mutation 
who were evaluable at 12 months, two were negative for 
minimal residual disease in bone marrow. All patients in 
molecular remission were in complete remission, based 
on Lugano criteria.
At a median follow-up of 17·8 months (IQR 14·7–20·9), 
treatment was discontinued in 34 (68%) of 50 patients 
because of progressive disease (in 17 [34%] patients), 
allo geneic stem-cell transplantation (in three [6%] patients), 
other treatment-related toxic effects (five [10%]), withdrawal 
of consent (three [6%]), death related to treatment 
(three [6%]), and for unspecified reasons (three [6%]). 
Adverse events led to dose reduction of lenalidomide in 














































































38 (76%, 63–86) 30 (79%, 64–89) 8 (73%, 43–90)
Complete 
remission
28 (56%, 42–69) 21 (55%, 40–70) 7 (64%, 35–85)
Partial 
remission
10 (20%, 11–33) 9 (24%, 13–39) 1 (9%, 2–38)
Stable disease 1 (2%, 0–1) 1 (3%, 0–14) 0 (0%, 0–0)
Progressive 
disease
5 (10%, 4–21) 3 (8%, 3–21) 2 (18%, 5–48)
Not evaluable* 6 (12%, 6–24) 4 (11%, 4–24) 1 (9%, 2–38)
Data are n (%, 95% CI). *Six patients were not evaluable because of withdrawal of 
consent (n=3) or treatment discontinuation because of treatment-related toxicity 
before response evaluation (n=3). One patient was not evaluable for TP53 
mutation status for technical reasons.
Table 2: Maximal responses to treatment in all patients and according to 
presence of TP53 mutation
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five (10%) of 50 patients and of ibrutinib in two (4%) 
patients.
The most common grade 1–2 non-haematological 
adverse events are reported in table 4. Gastrointestinal 
toxicity generally occurred in the early phase of 
treat ment, with a median duration of 2 months (IQR 1–3). 
One patient developed an intracerebral haematoma after 
12 months of treatment, leading to termination of 
ibrutinib; the patient recovered without residual 
symptoms and is still on maintenance treatment with 
rituximab. Atrial fibrillation was reported in four (8%) of 
50 patients (one was grade 3). The most common 
grade 3–4 non-haematological adverse events (occurring 
in >10% of patients) were gastrointestinal toxicity 
(in six [12%] of 50 patients), infections (in 11 [22%] patients), 
and cutaneous toxicity (in seven [14%] patients; 
all grade 3). One patient developed Guillain-Barré syn-
drome, requiring ventilator support for 3·5 months. 
Grade 3–4 haematological adverse events included neu-
tropenia in 19 (38%) patients, thrombocytopenia in 
six (12%) patients, and anaemia in one (2%) patient.
20 (40%) of 50 patients died during the study. The 
cause of death was disease progression in 17 (85%) of 
20 patients and treatment related in three (15%) patients 
(two [10%] because of sepsis and one [5%] because of 
embolic stroke). The patient with embolic stroke also had 
atrial fibrillation and had received apixaban as thrombo-
embolism prophylaxis, although apixaban had been 
stopped because of planned prostatic surgery.
Discussion
In this study, we showed that the triplet regimen of 
ibrutinib, rituximab, and lenalidomide was an active 
combination in patients with relapsed or refractory 
mantle cell lymphoma. 76% (95% CI 63–86) of patients 
had an overall response; however, the lower bound of the 
95% CI did not exceed the 68% (58–76) overall response 
with ibrutinib alone in a previous study,5 suggesting that 
the triplet regimen might not be superior to ibrutinib 
alone, although such cross-trial comparisons should be 
made with caution. In 2016, Wang and colleagues19 
presented data on the combination of ibrutinib and 
rituximab in a patient population that was similar to our 
population. The proportion of patients who achieved an 
overall response in that trial19 was slightly higher than 
that in this study (88% vs 76%), although similar when 
we excluded the six patients who either withdrew 
informed content or dropped out because of early toxicity 
in this study (88% vs 86%). The population in the study 
by Wang and colleagues19 was different to our population 
in terms of the proportion of patients with a low-risk 
MIPI score (44% in the study by Wang and colleagues vs 
16% in our trial) and the proportion of patients with 
refractory disease (70% in the study by Wang and 
colleagues vs 16% in our trial).
Addition of lenalidomide to ibrutinib and rituximab 
might increase the proportion of patients who have 
complete remission, which was 56% in this study. 
Previous studies8,10,19 reported complete responses in 44% 
of patients on ibrutinib and rituximab, in 36% of patients 
on rituximab and lenalidomide, and in 19% of patients 
on ibrutinib alone. However, 12-month progression-free 

























Negative 12 15 13 11 3 6 3 4
Positive 16 12 6 8 8 6 2 1
Molecular 
remission (%)
43% 56% 68% 58% 27% 50% 60% 80%
Table 3: Molecular remission in peripheral blood and bone marrow at 6, 12, 18, and 24 months
Grade 1–2* Grade 3 Grade 4 Grade 5
Haematological adverse events
Thrombocytopenia 8 (16%) 4 (8%) 2 (4%) 0 (0%)
Anaemia 8 (16%) 1 (2%) 0 (0%) 0 (0%)
Neutropenia NR 13 (26%) 6 (12%) 0 (0%)
Non-haematological adverse events
Gastrointestinal 34 (68%) 5 (10%) 1 (2%) 0 (0%)
Infections 18 (36%) 9 (18%) 2 (4%) 2 (4%)
Cutaneous 28 (56%) 7 (14%) 0 (0%) 0 (0%)
Fatigue 28 (56%) 1 (2%) 0 (0%) 0 (0%)
Muscle cramps 15 (30%) 3 (6%) 0 (0%) 0 (0%)
Respiratory 19 (38%) 1 (2%) 1 (2%) 0 (0%)
Neurological 19 (38%) 1 (2%) 0 (0%) 1 (2%)
Ocular 13 (26%) 0 (0%) 0 (0%) 0 (0%)
Psychiatric 6 (12%) 0 (0%) 0 (0%) 0 (0%)
Vascular 11 (22%) 5 (10%) 0 (0%) 0 (0%)
Renal 7 (14%) 0 (0%) 0 (0%) 0 (0%)
Atrial fibrillation NR 1 (2%) 0 (0%) 0 (0%)
Data are n (%). The denominator is 50. NR=not reported. *For grade 1–2 events, 
only those occurring in ≥10% of patients are reported.
Table 4: Treatment-emergent adverse events
Figure 3: Genetic aberrations detected in lymphoma cells in bone marrow at the time of relapse
Each column represents one patient (n=49). Blue squares indicate the presence of a deletion and red squares 
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survival in our study was lower than reported in a 
phase 2 trial19 of ibrutinib and rituximab (ie, without 
lenalidomide; 57% vs 75%), and median progression-free 
survival was not reached in that trial. In the phase 3 RAY 
trial10 with ibrutinib alone, the median progression-free 
survival was 14∙6 months, which was not much shorter 
than the 16 months in this study. A possible interpretation 
of these findings is that the triplet regimen might be 
associated with a deeper initial response, but that this 
response does not translate into longer progression-free 
survival.
In this study, patients with low-risk MIPI scores had 
good outcomes, with no such patients progressing 
during the study period. In three patients, the regimen 
was used as a bridge to allogeneic stem-cell transplan-
tation as a potentially curative strategy.
In-vitro and translational studies12,13 have suggested that 
rituximab and ibrutinib have antagonistic effects. This 
antagonism is believed to be due to off-target inhibitory 
effects of ibrutinib on interleukin-2 inducible tyrosine 
kinase (tyrosine-protein kinase ITK/TSK), potentially 
leading to inhibition of natural killer cells, as well as due 
to indirect mechanisms. At the time of initiation of this 
trial, we hypothesised that this antagonism might be 
reversed by lenalidomide because it is an activator of 
natural killer cells. However, subsequent in-vitro studies20 
have not confirmed this hypothesis, and the optimal 
sequence of ibrutinib and rituximab remains unknown. 
The in-vivo effect of combining immune modulation by 
ibrutinib with lenalidomide and antibodies targeting 
CD20 should be further investigated.11,21,22
The triplet regimen was associated with greater 
haematological toxicity, particularly neutropenia, than 
reported for the ibrutinib and rituximab combination.19 
This increased haematological toxicity is probably the 
cause of the increased incidence of grade 3–4 infections 
(22%) in our study. Cutaneous adverse events were also 
more common with the triplet regimen than with the 
doublet regimen, although we should be cautious about 
making direct comparisons between unrelated clinical 
trials; grade 3 reactions occurred in 14% of patients on 
the triplet regimen compared with 6% of patients on 
irutinib and rituximab.19 In a study15 of the triplet regimen 
in patients with untreated follicular lymphoma, the 
incidence of grade 3 rash was higher than observed in 
this study (36% vs 14%), indicating that this event might 
be less frequent in patients who have received previous 
chemotherapy than in those previously untreated with 
chemotherapy.
In a previous study,14 we identified TP53 mutations in 
about 10% of patients with untreated mantle cell lym-
phoma, and showed that, even with intensive immuno-
chemotherapy and autologous stem-cell trans plantation, 
the response to treatment and eventual outcome were poor 
for patients with TP53 mutations. Our interpretation of 
these findings is that TP53-mutated mantle cell lymphoma 
constitutes a phenotypically distinct and highly aggressive 
form of the disease, similar to the aggressive phenotype 
seen in TP53-mutated chronic lymphocytic leukaemia. 
Patients with mutations in TP53 should probably not 
receive standard immuno chemo therapy with or without 
autologous stem-cell trans plantation, but rather be 
included in experimental, front-line trials exploring novel 
targeted drugs. To our knowledge, this study is the first to 
show that non-chemotherapeutic approaches might be 
active in the subpopulation of patients with TP53 
mutations. We found that similar proportions of patients 
with and without TP53 mutations had an overall response 
and complete response, indicating a similarly high activity 
in these patients. Additionally, when correcting for other 
prognostic factors, no difference in progression-free 
survival was seen between patients with and without TP53 
mutations.
In a series from the European MCL Network,23 
combined deletion of CDKN2A and TP53 was associated 
with very poor outcomes in patients treated upfront with 
immunochemotherapy and autologous stem-cell trans-
plantation. These results were confirmed in our previous 
study14 in younger patients with mantle cell lymphoma 
from the Nordic MCL2 and MCL3 trials. Double deletions 
were detected in 8% of the European MCL cohort and in 
7% of the Nordic cohort. In this study, the frequency of 
double deletions was notably higher than in the previous 
studies, at 29%, but did not have an effect on prognosis. 
These differences might be explained by the substantially 
different setting of relapsed or refractory disease; 
however, the non-chemotherapeutic approach might 
have overcome the poor effect of these aberrations.
To our knowledge, previous studies of ibrutinib alone or 
in combination with other drugs have not included results 
on minimal residual disease. Here, we show that molecular 
remission might be achieved in a high proportion of cases 
and that negativity for minimal residual disease might be 
associated with improvement in both progression-free and 
overall survival. As shown previously,24 examination of 
minimal residual disease in bone marrow was more 
sensitive than examination in peripheral blood.
In conclusion, we showed that the combination of 
ibrutinib, lenalidomide, and rituximab was an active 
regimen in patients with relapsed or refractory mantle cell 
lymphoma, with high proportions of complete and 
molecular responses. However, our data did not support 
that the triplet regimen is superior to the combination of 
ibrutinib and rituximab or ibrutinib alone in these patients. 
Unlike chemotherapy-based regimens, this novel triplet 
combination seemed to overcome the negative prognostic 
effects of TP53 mutations and CDKN2A-TP53 deletions.
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